| Description: |
Breviscapine can reduce the inflammatory response, protect the lungs from inflammatory cascade responses by inhibiting the expression of IL-18 and ICAM-1. Breviscapine inhibits the increased levels of 4-HNE and 8-OHdG, and enhances the antioxidant capacity of cortex tissue. Breviscapine can treat coronary disease, breviscapine injection significantly ameliorates neurologic deficit, reduces infarct volume and water content, and suppresses the levels of NSE in a time-dependent manner, may the mechanism is by up-regulating the expression of Nrf2/HO-1 pathway . |
| In vivo: |
| J Sex Med. 2014 Sep;11(9):2143-52. | | Icariin combined with breviscapine improves the erectile function of spontaneously hypertensive rats.[Pubmed: 24912989] | The impaired erectile response in spontaneously hypertensive rats (SHR) is caused by increased signaling of RhoA/Rho-kinase and decreased signaling of nitric oxide (NO). Icariin improves erectile function via upregulating multitargets in NO/cyclic guanosine monophosphate (NO/cGMP) pathway, which Breviscapine accomplishes by downregulating RhoA/Rho-kinase pathway. To investigate the effect and mechanism of icariin combined with Breviscapine on the erectile function of SHR.
METHODS AND RESULTS:
Five 12-week-old male Wistar-Kyoto (WKY) rats and 20 age-matched male SHR were evenly randomized into WKY rats control group, SHR control group, icariin-treated group, Breviscapine-treated group, and combined treatment group treated by vehicle, icariin, Breviscapine, and icariin plus Breviscapine, respectively, by gavage for four successive weeks. Maximum intracavernosal pressure/mean arterial pressure (ICPmax/MAP) and the expression of endothelial nitric oxide synthase (eNOS), neuronal nitric oxide synthase (nNOS), phosphodiesterase type 5 inhibitors (PDE5), and Rho-associated, coiled-coil containing protein kinase 1 and 2 (ROCK1 and ROCK2) in the cavernous tissues were determined. The ICPmax/MAP in the combined treatment group was significantly increased compared with SHR control group, icariin-treated group, and Breviscapine-treated group. The expression of eNOS and nNOS was significantly higher in the combined treatment group than in SHR control group, icariin-treated group, and Breviscapine-treated group (P < 0.05). The expression of PDE5 was significantly lower in the icariin-treated group than in SHR control group (P < 0.05). The expression of ROCK1 was significantly lower in the combined treatment group than in other groups (P < 0.05). The expression of ROCK2 was significantly higher in SHR control group than in WKY rats control group, icariin-treated group, and combined treatment group (P < 0.05). Among these groups, the expression of eNOS and nNOS was the strongest, and ROCK1 was the lowest in WKY rats control group.
CONCLUSIONS:
Icariin combined with Breviscapine has synergistic effects on erectile function of SHR through different signal pathways. | | J Pharm Pharmacol. 2014 Jul;66(7):903-11. | | Improved oral bioavailability of breviscapine via a Pluronic P85-modified liposomal delivery system.[Pubmed: 24697705] | Breviscapine, a hydrophobic drug used for treating cardiovascular disease, was encapsulated in liposomes to improve its pharmaceutical characteristics. This study describes a novel liposome composition approach to specifically inhibit the P-glycoprotein efflux system.
METHODS AND RESULTS:
Breviscapine-loaded Pluronic P85-coated liposomes were prepared by the thin film hydration technique. The particle size, zeta potential and encapsulation efficiency of the formulations were characterized. In-vitro drug release and permeability of Caco-2 cells were investigated. In-vitro characteristics and pharmacokinetics of the liposomes were evaluated in rat studies. The Pluronic P85-modified liposomes dispersed individually and had an approximate diameter of 118.8 ± 4.9 nm and a zeta potential of -35.4 ± 1.5 mV. Encapsulation efficiency was more than 90%. The use of the P85-coated liposomes resulted in significantly (P<0.05) increased absorption of Breviscapine in Caco-2 cells and in 5.6-fold enhancement in its oral bioavailability in rats.
CONCLUSIONS:
The P85-modified liposomes for the oral delivery of Breviscapine were prepared using l-α-phosphatidylcholine (soy-hydrogenated) and cholesterol with a narrow size distribution. This method seems to effectively enhance the bioavailability of Breviscapine in rats. | | PLoS One. 2015 Jun 8;10(6):e0129969. | | Breviscapine Injection Improves the Therapeutic Effect of Western Medicine on Angina Pectoris Patients.[Pubmed: 26052709] | To evaluate the beneficial and adverse effects of Breviscapine injection in combination with Western medicine on the treatment of patients with angina pectoris.
METHODS AND RESULTS:
The Cochrane Central Register of Controlled Trials, Medline, Science Citation Index, EMBASE, the China National Knowledge Infrastructure, the Wanfang Database, the Chongqing VIP Information Database and the China Biomedical Database were searched to identify randomized clinical trials (RCTs) that evaluated the effects of Western medicine compared to Breviscapine injection plus Western medicine on angina pectoris patients. The included studies were analyzed using RevMan 5.1.0 software. The literature search yielded 460 studies, wherein 16 studies matched the selection criteria. The results showed that combined therapy using Breviscapine plus Western medicine was superior to Western medicine alone for improving angina pectoris symptoms (OR =3.77, 95% Cl: 2.76~5.15) and also resulted in increased electrocardiogram (ECG) improvement (OR=2.77, 95% Cl: 2.16~3.53).
CONCLUSIONS:
The current evidence suggests that Breviscapine plus Western medicine achieved a superior therapeutic effect compared to Western medicine alone. |
|
Cell. 2018 Jan 11;172(1-2):249-261.e12. doi: 10.1016/j.cell.2017.12.019.IF=36.216(2019)
Cell Metab. 2020 Mar 3;31(3):534-548.e5. doi: 10.1016/j.cmet.2020.01.002.IF=22.415(2019)
Mol Cell. 2017 Nov 16;68(4):673-685.e6. doi: 10.1016/j.molcel.2017.10.022.IF=14.548(2019)
ACS Nano. 2018 Apr 24;12(4): 3385-3396. doi: 10.1021/acsnano.7b08969.IF=13.903(2019)
Nature Plants. 2016 Dec 22;3: 16206. doi: 10.1038/nplants.2016.205.IF=13.297(2019)
Sci Adv. 2018 Oct 24;4(10): eaat6994. doi: 10.1126/sciadv.aat6994.IF=12.804(2019)
